Answer Amyotrophic Lateral Sclerosis

What Answer Amyotrophic Lateral Sclerosis does

Answer ALS (legally Answer ALS Foundation) is a 501(c)(3) nonprofit research consortium headquartered in New Orleans, Louisiana, founded in 2014 following a 2013 ALS Summit convened by Steve Gleason and Team Gleason. The organization coordinates a global ALS research effort involving 8 major ALS clinics at Johns Hopkins, Massachusetts General Hospital, Cedars-Sinai, Washington University, Ohio State University, Emory, Northwestern, and Texas Neurology, alongside dozens of research institutions and over 1,100 enrolled participants. Its core product is the Neuromine Data Portal, a Microsoft Azure-hosted open-access platform that integrates multi-omics data (genomics, transcriptomics, epigenomics, proteomics, metabolomics) with clinical information across more than 2,500 ALS patient profiles and over 150 TB of harmonized data — described as the world's largest ALS research repository.

The technology stack combines patient-derived induced pluripotent stem cell (iPSC) line generation and motor neuron differentiation (in partnership with the Cedars-Sinai Biomanufacturing Center), robotic microscopy for live-cell analysis, the open-source Galaxy platform for bioinformatics pipelines, and machine learning applied to multi-omics for ALS subtype identification, biomarker discovery, and predictive modeling. Companion programs include the iPSC Repository (nearly 1,000 ALS patient lines distributed), Champion Insights (a remote-participation study of up to 500 elite athletes, military veterans, and first responders investigating elevated ALS risk), and LADDIA — an AI drug discovery initiative with GATC Health, Pennington Biomedical Research Center, and Tulane University.

As a nonprofit, Answer ALS does not generate traditional revenue; the platform is offered free to qualified researchers worldwide. Funding comes from corporate sponsors (American Airlines, Caterpillar, Microsoft in cloud compute, Stay Strong vs ALS, Augie's Quest), federal grant exposure (now constrained by congressional CDMRP/NIH cuts), and disease-focused grants (MDA, axeALS). The organization's customer base is composed of academic researchers and pharmaceutical/biotech drug developers who consume data and biosamples to inform ALS drug discovery, biomarker identification, and clinical trial design.

Name

Answer Amyotrophic Lateral Sclerosis

Legal name

Answer ALS Foundation

Website

https://answerals.org

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Answer ALS is a nonprofit research consortium that operates Neuromine, the world's largest open-access ALS data portal integrating multi-omics and clinical data from 2,500+ patients for academic and pharma researchers.

Ownership category

akta.pro rank

Product category

Biomedical Research Data Platform

NAICS

Web Search Portals and All Other Information Services (51929), Libraries and Archives (51921), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Medical Imaging AI (HDAAAEAH)

Keywords

• ALS research data
• Multi-omics analysis
• Stem cell repository
• Open-access research
• Biomedical data platform

Headquarters

HQ city

New Orleans

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Pricing tiers

Distribution channels1 record

Marketing channels3 records

Core offering

Answer ALS operates the Neuromine Data Portal, the world's largest open-access ALS research repository providing harmonized multi-omics and clinical data from more than 2,500 ALS patient profiles, available at no cost to qualified researchers worldwide. The organization also operates the world's largest ALS patient-derived iPSC repository in partnership with Cedars-Sinai, and runs research initiatives including Champion Insights and LADDIA (AI drug discovery). All assets are openly shared to accelerate global ALS therapeutic development.

Product overview

Answer ALS operates as a research consortium rather than a traditional software product company, offering the Neuromine Data Portal as its core open-access platform for ALS research data. The platform integrates multi-omics data (genomics, transcriptomics, proteomics, epigenomics, metabolomics) with clinical data from over 2,500 patient profiles. Supporting programs include Champion Insights (a remote-participation study of high-risk populations), the iPSC Repository (patient-derived stem cell lines with Cedars-Sinai), and LADDIA (AI-powered drug discovery initiative). All resources are openly shared with the global research community to accelerate ALS therapeutic development.

Differentiator

Problem solved

Functional benefit

Brands

• Neuromine: The Neuromine Data Portal is Answer ALS's cloud-based data platform that hosts the world's largest open-access ALS research repository, integrating multi-omics, clinical, and cellular datasets along with links to iPSC lines and biosamples.
• Champion Insights

Products and services

• Neuromine Data Portal Primary open-access cloud-based data platform hosting the world's largest ALS research repository with over 150 TB of multi-omics and clinical data from more than 2,500 patient profiles. Enables researchers worldwide to query, filter, and analyze genomic, transcriptomic, proteomic, epigenomic, and clinical data at no cost.
• Champion Insights Remote-participation research study investigating elevated ALS risk among high-performance athletes, military veterans, and first responders. Enrolls 500 participants contributing blood samples and clinical data from home to analyze genetic, biological, and environmental factors linked to higher ALS incidence.
• iPSC Repository World's largest ALS patient-based induced pluripotent stem cell repository created in partnership with Cedars-Sinai Biomanufacturing Center. Nearly 1,000 unique stem cell lines from ALS patients and over 100 healthy controls, differentiated into motor neurons for disease modeling and drug discovery.
• LADDIA (Louisiana AI Drug Development Infrastructure) AI-powered drug discovery collaboration with GATC Health, Pennington Biomedical Research Center, and Tulane University. Uses proprietary AI platform to identify druggable ALS targets with high predictive accuracy from multiomics data.

Quantifiable outcome

• Enables researchers worldwide to access standardized ALS patient data without the significant time and cost of data collection

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature1 record

Partnerships

Five partnerships are on record, tiered core.

• MicrosoftcoreTechnology or Integration · 1 January 2020Microsoft provided $1 million in cloud computing resources to support the Neuromine Data Portal infrastructure and data processing capabilities. Azure cloud platform enables scalable storage and analysis of ALS research data.
• ALS Therapy Development Institute (ALS TDI)coreStrategic or Co-development PartnerCollaborative research partnership combining Answer ALS patient data with ALS TDI's therapeutic screening programs. Joint effort to accelerate drug discovery using patient-derived stem cells.
• Cedars-SinaicoreStrategic or Co-development PartnerClinical and research partnership with Cedars-Sinai Medical Center for patient recruitment, stem cell line development, and genomic analysis.
• Johns Hopkins University (Robert Packard Center for ALS Research)coreStrategic or Co-development PartnerResearch partnership with the Robert Packard Center for ALS Research at Johns Hopkins University for data analysis, methodology development, and scientific collaboration.
• Massachusetts General HospitalcoreStrategic or Co-development PartnerClinical partnership with Massachusetts General Hospital for ALS patient enrollment, clinical data collection, and biomarker research.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ALS Therapy Development Institute (ALS TDI): ALS TDI is the largest nonprofit biotech focused solely on ALS, running its own preclinical research and the ARC clinical study. Answer ALS already partners with ALS TDI on data sharing and Champion Insights, and its ARC dataset was integrated into Neuromine in November 2025 — making them direct peers in ALS translational research with overlapping consortium models.
• Target ALS: Target ALS is a public-private partnership that funds collaborative ALS research and maintains its own postmortem tissue and multi-omics biorepository. It serves the same academic and pharma researchers as Answer ALS and represents the closest alternative large-scale ALS research consortium with a shared data-sharing mission.
• Project MinE: Project MinE is an international ALS genomics consortium performing whole-genome sequencing on thousands of ALS patients across Europe, the US, and beyond. It is comparable as a large-scale, open-access ALS data generation project with a similar multi-country academic-clinic operational model.
• Robert Packard Center for ALS Research at Johns Hopkins: Packard is the academic research center that incubated much of the Answer ALS scientific agenda and shares leadership (Jeffrey Rothstein, now Jeffrey Keller). It is a core scientific partner of Answer ALS but operates as its own independent ALS research center with overlapping investigator base and portfolio.

Broad incumbents

• Muscular Dystrophy Association (MDA): MDA funds ALS research and care across a wider neuromuscular disease portfolio and is an active grant funder of Answer ALS (e.g., the $200K Champion Insights grant). It is comparable as a large nonprofit research funder with overlapping investigator networks and shared ALS program priorities.
• The ALS Association (ALSA): ALSA is the largest US ALS nonprofit, funding research, advocacy, and care services. While broader in scope than Answer ALS (which focuses on research infrastructure), ALSA's research grant program and Global Genes partnerships make it an incumbent in the same disease-specific funding ecosystem, sharing many institutional donors and investigators.
• NIH NeuroBioBank / NINDS Repository: The NIH NeuroBioBank and NINDS curate large postmortem and biofluid repositories for ALS and other neurodegenerative diseases. They serve a similar researcher base with comparable standardized multi-site tissue and data collection, positioning them as a federally-funded incumbent in the disease-specific biorepository space.

Others

• Team Gleason: Team Gleason is the founding patient-advocacy organization behind Answer ALS, providing people, technology, and advocacy infrastructure. Although Steve Gleason's 2013 ALS Summit catalyzed Answer ALS, the two organizations remain legally and operationally distinct, making Team Gleason an adjacent ecosystem partner rather than a direct competitor.
• Cedars-Sinai Biomanufacturing Center (iPSC Core): Cedars-Sinai houses the iPSC manufacturing capacity that produces the world's largest ALS patient iPSC repository jointly with Answer ALS. It is comparable as a critical operational partner enabling the biological resource arm of the platform, sharing scientific leadership on ALS stem-cell modeling.

Emerging players

• GATC Health: GATC Health is an AI-driven drug discovery company that partnered with Answer ALS to form LADDIA. While not a direct competitor, GATC applies AI to multi-omics data — the same core activity Answer ALS enables — making it a comparably positioned emerging player in computational ALS drug discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AnswerALS
• YouTubeyoutube.com/@answerals8963/videos
• Facebookfacebook.com/answerals
• LinkedInlinkedin.com/company/answer-als
• Instagraminstagram.com/answerals

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Answer Amyotrophic Lateral Sclerosis